<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04838678</url>
  </required_header>
  <id_info>
    <org_study_id>STU2020-0749</org_study_id>
    <nct_id>NCT04838678</nct_id>
  </id_info>
  <brief_title>Sympathetic Transduction in Obesity-associated Hypertension (OB-HTN)</brief_title>
  <acronym>OB-HTN</acronym>
  <official_title>Sympathetic Neural Patterns and Transduction in Obesity-associated Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to understand how the nervous system communicates to blood&#xD;
      vessels to increase blood pressure during stress. The study will also investigate how&#xD;
      hypertension and obesity influence the nervous system and vascular function. The study will&#xD;
      involve measuring sympathetic nervous system activity and blood flow during common laboratory&#xD;
      physiological stress protocols (e.g. hypoxia, exercise), and in response to infusion of drugs&#xD;
      that cause vasodilation or vasoconstriction.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 18, 2021</start_date>
  <completion_date type="Anticipated">September 2025</completion_date>
  <primary_completion_date type="Anticipated">September 2025</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood flow measured by doppler ultrasound</measure>
    <time_frame>Acutely on the day of study</time_frame>
    <description>brachial and femoral artery blood flow</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Muscle sympathetic nervous system activity</measure>
    <time_frame>Acutely on the day of study</time_frame>
    <description>recording of sympathetic nervous system activity from the peroneal or radial nerve</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Hypertension</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Healthy Control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy age matched controls with no history of cardiovascular disease and normal bodyweight</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hypertensive</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hypertensive adults who are not obese</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Obese</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Obese adults who are not hypertensive</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Obese-hypertensive</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Obese adults who are being treated for hypertension</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neuropeptide Y</intervention_name>
    <description>intra-arterial infusion of neuropeptide Y</description>
    <arm_group_label>Healthy Control</arm_group_label>
    <arm_group_label>Hypertensive</arm_group_label>
    <arm_group_label>Obese</arm_group_label>
    <arm_group_label>Obese-hypertensive</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Control - BMI&lt;30, age 30-55&#xD;
&#xD;
          -  Hypertensive - BMI&lt;30, age 30-55, diagnosis of hypertension by 24-hour ambulatory&#xD;
             blood pressure monitoring Obese- BMI&gt;30, age 18-70 Obese-hypertensive- BMI&gt;30, age&#xD;
             30-55, diagnosis of hypertension by 24-hour ambulatory blood pressure monitoring&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        All groups - presence of other significant cardiovascular disease, renal disease, history&#xD;
        of smoking, diabetes,&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Christopher M Hearon, Ph.D.</last_name>
    <phone>214-345-4624</phone>
    <email>christopher.hearon@utsouthwestern.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mary Childers</last_name>
    <phone>214-345-6459</phone>
    <email>marychilders@texashealth.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>CHristopher Hearon</last_name>
      <phone>815-540-5612</phone>
      <email>christopherhearon@texashealth.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>April 6, 2021</study_first_submitted>
  <study_first_submitted_qc>April 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 9, 2021</study_first_posted>
  <last_update_submitted>November 18, 2021</last_update_submitted>
  <last_update_submitted_qc>November 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>Christopher Hearon</investigator_full_name>
    <investigator_title>Assistant Instructor</investigator_title>
  </responsible_party>
  <keyword>NPY</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

